Clinical Report: SSTR2-Targeted Therapy Combined with 177Lu-DOTATATE
Overview
Expand on the patient's treatment history and specify the nature of 'treatment-resistant' meningioma.
Background
Meningiomas are the most common primary intracranial tumors in adults, with limited treatment options beyond surgery and radiation. The expression of somatostatin receptor 2 (SSTR2) in these tumors provides a rationale for targeted therapies, including somatostatin analogs like octreotide. Investigating novel treatment combinations, such as SSTR2-targeted radionuclide therapy, is crucial for improving outcomes in patients with refractory meningiomas.
Data Highlights
No numerical data available in the article.
Key Findings
The patient received 177Lu-DOTATATE (7.4 GBq) and octreotide (40 mg every 8 weeks) for four cycles.
Post-treatment MRI showed stable disease with an 11.5% reduction per RANO-Meningioma criteria.
The treatment was discontinued due to the patient's death from non-treatment related causes 2.5 months after the last dose.
Combination therapy represents a promising approach for refractory meningioma, despite limited existing evidence.
Previous studies indicate that octreotide combined with PRRT has shown improved progression-free survival in neuroendocrine tumors.
Clinical Implications
The findings suggest that SSTR2-targeted therapy combined with 177Lu-DOTATATE and octreotide may offer a new treatment avenue for patients with refractory meningiomas. Clinicians should consider this combination in the context of clinical trials and individualized patient care.
Conclusion
Reiterate the necessity for further studies and potential implications for clinical practice.
by Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, Eleanor Chu, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Hansen Bow, Michelle Zheng, Shyam M. Srinivas
